AAV1.tMCK.NT-3 gene therapy improves phenotype in Sh3tc2−/− mouse model of Charcot–Marie–Tooth Type 4C
2024

Gene Therapy Improves Symptoms in Mouse Model of Charcot–Marie–Tooth Disease

Sample size: 31 publication Evidence: high

Author Information

Author(s): Ozes Burcak, Tong Lingying, Moss Kyle, Myers Morgan, Morrison Lilye, Attia Zayed, Sahenk Zarife

Primary Institution: The Abigail Wexner Research Institute, Nationwide Children’s Hospital

Hypothesis

Can AAV1.NT-3 gene therapy improve the phenotype in a mouse model of Charcot–Marie–Tooth Type 4C?

Conclusion

AAV1.NT-3 gene therapy significantly improved functional and electrophysiological outcomes in the Sh3tc2−/− mouse model of CMT4C.

Supporting Evidence

  • NT-3 gene therapy improved functional outcomes such as rotarod and grip strength.
  • Electrophysiological studies showed increased nerve conduction velocity in treated mice.
  • Histopathological analysis revealed improved myelination and Schwann cell density.

Takeaway

Scientists used a special gene therapy to help sick mice with a nerve disease feel better and move better.

Methodology

The study involved injecting AAV1.NT-3 into the muscles of Sh3tc2−/− mice and assessing their functional and electrophysiological outcomes over six months.

Limitations

The study was conducted in a mouse model, which may not fully replicate human conditions.

Participant Demographics

The study involved 15 Sh3tc2−/− mice (7 females and 8 males) and 16 control mice (8 females and 8 males).

Statistical Information

P-Value

0.0014

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1093/braincomms/fcae394

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication